Auris Health是一家私人持股的医疗机器人公司，该公司拥有一种肺癌活检工具，是医疗机器人公司Intuitive Surgical的竞争对手。强生考虑斥资20亿美元收购Auris Health。$强生(JNJ)$ $达芬奇手术机器人(ISRG)$ #并购#
Johnson & Johnson (JNJ) reportedly may bid for Auris Health, a privately held robotic surgery player with a lung cancer biopsy tool that rivals Intuitive Surgical (ISRG). J&J shares slipped just ahead of Wednesday's opening bell.
据报道，强生公司（ JNJ ）可能收购 Auris Health ，一家私人持股的机器人外科医生，该公司拥有一种肺癌活检工具，与 Intuitive Surgical （ ISRG ）竞争。强生股价在周三开盘前下跌。
Bloomberg reported the rumor early Wednesday, citing "people familiar with the matter." One person reportedly said Redwood City, Calif.-based Auris is valued around $2 billion. The report follows lackluster guidance from J&J on Tuesday for sales to be flat to up just 1% in 2019.
彭博周三早些时候报道了这一传闻，称“知情人士”。据报道，一个人说加州红木城。-总部位于 Auris 的价值约为20亿美元。这份报告发布之前，强生周二发布的销售业绩平平，2019年仅增长1%。
J&J declined to comment on "market rumors and speculation" in an email to Investor's Business Daily.
强生拒绝在发给《投资者商业日报》的电子邮件中对“市场传言和投机”发表评论。
本文未完，阅读全文点击：强生计划斥资20亿美元收购Auris Health，以抗衡Intuitive Surgical